Kenvue stock (US49177J1025): General Counsel sells $679K in shares

Kenvue Inc., the consumer health giant spun off from Johnson & Johnson, saw insider selling activity as General Counsel Matthew Orlando offloaded 38,491 shares of common stock on May 8, 2026. The transaction occurred at a weighted average price of $17.6583 per share, totaling approximately $679,690, according to an SEC Form 4 filing as of May 2026. Following the open-market sale, Orlando holds no direct ownership in Kenvue common stock.

This move comes amid positive Q1 2026 results for Kenvue, with sales reaching $3.909 billion and net income of $474 million, as reported in recent filings and coverage by Simply Wall St as of May 2026. Kenvue shares are listed on the NYSE under ticker KVUE, relevant for US retail investors tracking consumer staples exposure.

As of: 13.05.2026

By the editorial team – specialized in equity coverage.

Kenvue: core business model

Kenvue operates as a leading consumer health company, focusing on self-care, skin health and beauty, and essential health products. Iconic brands such as Tylenol, Neutrogena, Listerine, and Band-Aid drive its portfolio. The company was spun off from Johnson & Johnson in 2023 and maintains a strong US market presence, with products available in major retailers nationwide.

Revenue is generated primarily through over-the-counter medications, skincare, and oral care, serving everyday consumer needs. Kenvue emphasizes innovation in wellness and hygiene, positioning itself for steady demand in the resilient consumer health sector attractive to US investors seeking defensive plays.

Main revenue and product drivers for Kenvue

Self-Care, including pain relief and cough/cold remedies like Tylenol, represents a core revenue pillar. In Q1 2026, overall sales hit $3.909 billion, reflecting robust performance across segments, per company disclosures cited in Simply Wall St as of May 2026. Skin Health and Beauty, led by Neutrogena, contributes significantly, bolstered by US consumer spending on personal care.

Essential Health products like Band-Aid and Listerine provide diversified streams. Kenvue's market cap stood at $33.54 billion USD as of May 2026, ranking it among top global players, according to CompaniesMarketCap as of May 2026.

Industry trends and competitive position

The consumer health industry benefits from aging populations and rising wellness focus in the US, where Kenvue holds strong shelf space in pharmacies and supermarkets. Competitors include Procter & Gamble and Haleon, but Kenvue's J&J heritage provides brand loyalty advantages.

Why Kenvue matters for US investors

Listed on NYSE, Kenvue offers US investors direct access to a defensive sector with stable demand. Its exposure to essential products shields against economic volatility, making it relevant for portfolios balancing growth and staples amid US market dynamics.

Conclusion

The recent insider sale by Kenvue's General Counsel highlights executive activity amid solid Q1 results and a stable market cap. Investors monitor such transactions alongside operational metrics like $3.909 billion in Q1 sales. Kenvue remains a key player in US consumer health, with its NYSE listing facilitating retail access.

Disclaimer: This article does not constitute investment advice. Stocks are volatile financial instruments.